Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BrightGene

- PMLiVE

COVID-19 booster dose programme planned for September launch in Britain

The programme will be conducted in two stages for a range of priority groups

- PMLiVE

Cambridge University scientists identify 160 new drugs with COVID-19 repurposing potential

Scientists highlighted the potential of two drugs, one for rheumatoid arthritis and one for malaria

- PMLiVE

WHITE PAPER: From bench to bedside in one year – how the race for a COVID-19 vaccine will change the future of drug development

In this edition of MAGNIFI, we discuss the factors behind this acceleration in development of the COVID-19 vaccines and what this might mean for the future of pharma

IGNIFI

- PMLiVE

Final data shows CureVac’s COVID-19 vaccine is only 48% effective

New data shows slight improvement over previously reported 47% overall efficacy in interim analysis

Report

Digital Health Tools - Physician Trends

Research Partnership

- PMLiVE

Moderna says its COVID-19 vaccine appears effective against Delta and other variants

Earlier this year, the company revealed early evidence that its booster jabs may be effective against ‘variants of concern’

- PMLiVE

EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy

The five therapeutic candidates include a repurposed arthritis med and monoclonal antibodies

- PMLiVE

Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug

Pardes’ lead oral antiviral drug candidate is designed to inhibit the main protease of SARS-CoV-2

- PMLiVE

Stick or twist? The future of HCP engagement

The Covid-19 pandemic forced companies to be more agile and rethink their value offering when engaging with HCPs, but what does the future of HCP engagement look like?

Say Communications

- PMLiVE

Healthcare tech: the driving force behind value-based care?

In 2020, healthcare technology investment went into overdrive. We speak to Sunny Kumar, Partner at GSR Ventures, to find out how COVID‑19 has transformed the industry and whether healthcare technology...

Avalere Health

- PMLiVE

Study finds mixed vaccine schedules provide strong immune response against COVID-19

And AZ's Vaxzevria COVID-19 vaccine shows strong immune responses following a delayed second dose

- PMLiVE

Stick or Twist? Healthcare brands in a (post) COVID-19 world

How have our perceptions of healthcare brands and our purchasing habits changed during the COVID-19 pandemic?

Say Communications

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links